XML 148 R54.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Revenue - Remaining Performance Obligation (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019
--- | --- | ---
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 87,225 |
Collaboration Revenue by Strategic Collaborator |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 327,700 |
Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 396,830 | $ 401,782
Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 77,500 |
Performance period | 8 years 3 months |
Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 9,700 |
Performance period |  |
VEGF Exercise 2016 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 60,312 | 57,871
VEGF Exercise 2016 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 41,877 |
Performance period | 4 years 3 months |
PCVSAV Agreement |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 213,360 | 213,050
PCVSAV Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 51,007 |
Performance period | 3 years 3 months |
Vertex Agreement |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations |  | $ 24,400
Vertex Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Performance period | 1 year |

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |